New York's attorney general filed a federal lawsuit Monday seeking to stop a manufacturer from...
Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and...
Actavis and Forest Labs today announced that C. David Nicholson, PhD will be appointed Senior...
Adamas Pharmaceuticals has received a $25M milestone payment from Forest Laboratories related to the development of MDX-8704. MDX-8704, a fixed-dosed combination of memantine HCl extended release capsules and donepezil HCl, is being developed as a once daily therapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the United States.
Actavis today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year.
Forest said Monday that it will spend as much as $1.5 billion to buy Furiex Pharmaceuticals Inc. in a deal that will give it one of the broadest product lines for gastrointestinal disease treatments.
The company leading the legal challenge against birth control coverage under the new health care law offers its workers a retirement plan that includes investments in companies making contraceptive and abortion drugs.
Flush with cash and high stock prices, companies are buying up the competition at levels not seen since the dotcom bubble. And with Washington providing more clarity on government spending plans, CEOs are more confident their expansion hopes will pan out — especially if the economy keeps growing.
Forest Laboratories and Adamas Pharmaceuticals have jointly announced Forest’s submission of a New Drug Application (NDA) to the Food and Drug Administration for a fixed-dose combination (FDC) of memantine HCl extended release (ER) and donepezil HCl for the treatment of moderate to severe dementia of the Alzheimer’s type.
Forest Labs said Monday it completed its $2.9 billion purchase of Aptalis, a company that makes treatments for gastrointestinal problems and cystic fibrosis.Forest said the acquisition of Aptalis will give it about $700 million in revenue in its next fiscal year.
The growth prospects for Forest Laboratories, as well as its cost cutting, have garnered praise from industry watchers after the specialty drugmaker reported third-quarter earnings and revenue that trumped Wall Street expectations.
Shares of Forest Laboratories jumped Friday before markets opened and after a Credit Suisse said the drug developer "is in the early innings of a multi-year rejuvenation story."
Forest Laboratories, Inc. today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal (GI) and Cystic Fibrosis company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm
Forest Laboratories, Inc. today announced appointments to its executive leadership team. The appointments are part of Forest’s announced plans to flatten and broaden the organization as part of Project Rejuvenate.
Forest Laboratories says it plans to cut about 500 jobs as part of a plan to trim $500 million in costs over the next two years. The company also plans to buy back at least $400 million in company stock and agreed to pay $240 million for the U.S. marketing rights to Saphris.
Under the terms of the agreement, Forest will make an upfront payment of $240 million and additional payments to Merck based on defined sales milestones. Merck will remain responsible for product supply. Forest will assume responsibility for continued commercialization, including completing certain post marketing studies of Saphris following a transition period.
Forest Labs said regulators want more information on the drugmaker's potential schizophrenia treatment cariprazine before they decide whether to approve the drug. The potential drug aims to treat bipolar I disorder, which is also known as manic-depressive illness and characterized by unusual shifts in a person's mood, energy level or ability to carry out daily tasks.
Ceftazidime/Avibactam Combination Receives Qualified Infectious Disease Product (QIDP) Designation from FDASeptember 13, 2013 7:52 am | News | Comments
Forest Laboratories has announced that the FDA has designated its investigational drug, ceftazidime/avibactam, a qualified infectious disease product (QIDP). The QIDP designation was created by the Generating Antibiotic Incentives Now (GAIN) Act, which was part of the FDA Safety and Innovation Act (FDASIA), which was signed into law in 2012.
Forest Laboratories, Inc. today announced that Brenton L. Saunders, 43, the former Chief Executive Officer of Bausch + Lomb, has been appointed Forest's Chief Executive Officer and President, effective October 1, 2013. Mr. Saunders, who will succeed Howard Solomon, has served as a Forest director since August 2011.
Forest Laboratories and Almirall SA will delay their filing for approval of a combination lung disease drug. Forest and Almirall are developing a combination of Forest's drug Tudorza and the asthma drug formoterol as a treatment for chronic obstructive pulmonary disease.
Forest Laboratories said Friday that the Food and Drug Administration has approved its depression drug Fetzima, and the drug should be available in the fourth quarter. Forest makes Alzheimer's treatment Namenda and another antidepressant, Lexapro, whose sales have shrunk because of generic...
Forest Laboratories, Inc. and Forest Laboratories Holdings, Ltd. announced that they have entered into a settlement agreement with Amerigen Pharmaceuticals, Inc. and Amerigen Pharmaceuticals, Ltd. in patent infringement litigation brought by Forest in response to Amerigen's abbreviated new drug application (ANDA) seeking approval to market generic versions of Forest's BYSTOLIC® (nebivolol) tablets.
Forest Laboratories, Inc. today announced that, pursuant to an agreement with Carl C. Icahn and affiliated entities, its Board has appointed Vincent J. Intrieri as a new independent member of its Board of Directors. As part of the agreement, Mr. Icahn has agreed to vote the shares that he controls in support of Forest’s 11 director nominees and not run a proxy contest at the Company’s 2013 annual meeting.
Forest Laboratories Inc.'s fiscal fourth-quarter earnings plunged 76 percent, as the drug developer's revenue continued to take a hit from a key patent loss. The New York company said Tuesday that it earned $45.4 million, or 17 cents per share, in the three months that ended March 31. That...
Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch SurveyMarch 4, 2013 7:59 am | News | Comments
More than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
Forest Laboratories Inc. has submitted the potential oral schizophrenia and bipolar treatment cariprazine to the Food and Drug Administration for approval.
Forest Laboratories, Inc. and Pierre Fabre Laboratories today announced that Forest has submitted a New Drug Application (NDA) to the FDA for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.
- Page 1